# Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

> **NCT03264989** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Sickle Cell Disease (SCD)

## Interventions

- **DRUG:** crizanlizumab

## Key facts

- **NCT ID:** NCT03264989
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-19
- **Primary completion:** 2023-06-26
- **Final completion:** 2023-06-26
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03264989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03264989, "Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03264989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*